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target lobe. All patients were closely monitored and were 
not discharged before the fourth day after BLVR.  Results: 
Twenty patients with FEV 1  ≤ 20% predicted were included in 
the analysis. Lung volume reduction was achieved in 65% of 
the cases. Pneumothorax occurred in 4 cases (20%). No pa-
tient died. Lung function and exercise tolerance improved 
after 1 and 3 months, respectively.  Conclusions: BLVR with 
valves can be safely performed in patients with FEV 1  ≤ 20% 
predicted when close postprocedural monitoring is provid-
ed. Improvement in lung function and exercise capacity can 
be achieved.  © 2016 S. Karger AG, Basel 
 Introduction 
 Surgical lung volume reduction has been shown to im-
prove lung function, exercise capacity, and quality of life 
in lung emphysema patients  [1] . Bronchoscopic lung vol-
ume reduction (BLVR) by placement of endobronchial 
valves is a more recent, less invasive development to in-
duce atelectasis of the most damaged lobe. In selected
patients with heterogeneously distributed emphysema, 
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 Abstract 
 Background: Bronchoscopic lung volume reduction (BLVR) 
with valves has been shown to improve lung function, exer-
cise capacity, and quality of life in patients with emphysema, 
but only few patients with forced expiratory volume in 1 s 
(FEV 1 )  ≤ 20% predicted have been included in former stud-
ies. Although the procedure can be performed safely, pneu-
mothorax is a frequent complication, which can be critical 
for these very severely diseased patients.  Objectives: The 
aim of the study was to assess the safety of BLVR in patients 
with a very advanced stage of emphysema, as indicated by 
FEV 1  ≤ 20% predicted.  Patients and Methods: Patients in 
whom BLVR was performed between January 2013 and Au-
gust 2015 were included in this analysis if their baseline pre-
dicted FEV 1 was  ≤ 20%. BLVR, performed only if collateral 
ventilation was absent, achieved complete occlusion of the 
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BLVR can achieve a significant increase in lung function, 
exercise capacity, and quality of life and a decrease in hy-
perinflation and dyspnea on exertion  [2, 3] . As a prereq-
uisite, interlobar collateral ventilation of the target lobe 
must be excluded, for instance, by a Chartis physiological 
collateral ventilation measurement  [4] .
 In the NETT trial of surgical lung volume reduction, 
the mortality of patients with very advanced destruction 
of the lung, resulting in forced expiratory volume in 1 s 
(FEV 1 )  ≤ 20% predicted, was significantly higher than in 
subjects with higher FEV 1  [1] . Only few “low-FEV 1 ” pa-
tients were included in subsequent trials for surgical or 
bronchoscopic LVR. Patients with severe emphysema 
suffer from significantly impaired gas exchange and di-
minished ventilatory capacity. Comorbidities are also fre-
quent in these patients, resulting in an increased risk of 
periinterventional complications for any form of invasive 
treatment  [5] . It is, therefore, unknown whether BLVR 
with valves can be performed safely in low-FEV 1 patients, 
and the aim of this study was to examine this aspect.
 Materials and Methods 
 Patients 
 This retrospective analysis included patients who underwent 
BLVR treatment with endobronchial valves in our tertiary care 
center between January 2013 and August 2015 if their baseline 
FEV 1 was  ≤ 20% predicted. The ethics committee of the University 
of Essen approved the study protocol. All patients with severe hy-
perinflation and advanced emphysema had been treated with en-
dobronchial valves (Zephyr © Endobronchial Valve; Pulmonx, 
Inc., Redwood City, CA, USA). For each patient, heterogeneity of 
the emphysema was visually assessed by high-resolution comput-
ed tomography (HRCT) and perfusion scan in a multidisciplinary 
conference that included, in addition to general and intervention-
al pulmonologists, a lung transplant physician and a thoracic sur-
geon experienced in lung volume reduction surgery. In this confer-
ence, the general suitability for BLVR treatment was discussed, and 
only patients with heterogeneously distributed emphysema were 
selected for BLVR. Patients with no or hardly any perfusion in the 
target lobe were classified as very heterogeneous. As volumetric 
HRCT scans were not available in our institution before September 
2015, volumetric emphysema quantification data could not be as-
sessed. All patients underwent a pulmonary rehabilitation pro-
gram and had stopped smoking for at least 6 months prior to BLVR 
indication. Patients who had been listed for lung transplantation 
were also evaluated for BLVR, which was then used to bridge the 
time to lung transplantation. Echocardiography was performed to 
exclude significant cardiac insufficiency. Significant hypoxemia or 
hypercapnia was treated by oxygen supply or noninvasive ventila-
tion. Patients with a history of any thoracic surgery or lung volume 
reduction, with sputum excess or more than 2 exacerbations per 
year, were excluded from BLVR treatment
 Valve Placement 
 In all patients undergoing a BLVR procedure, a laryngeal mask 
or a rigid bronchoscope was placed under deep sedation that al-
lowed spontaneous breathing. The target lobe was determined 
from the HRCT scan and perfusion scans. A Chartis measurement 
was performed at the beginning of the procedure to assess and ex-
clude the presence of interlobar collateral ventilation of the target 
lobe  [6] . Patients with collateral ventilation were deemed inade-
quate for valve placement. When the endoscopist was uncertain 
about the most appropriate target lobe (e.g., when there was simi-
larly reduced perfusion in more than 1 target lobe), a lobar endo-
bronchial gas exchange measurement was performed using a ded-
icated in-house developed equipment (Super-Chartis) as described 
by Freitag et al.  [7] . In this case, the lobe with poorest gas exchange 
was selected for treatment. After these 2 measurements, endobron-
chial valves (Zephyr © ) were placed to achieve complete occlusion 
of the target lobe. According to our standard protocol, all patients 
were monitored for 24 h in the intensive care unit (ICU) and were 
not discharged from hospital before the fourth day after BLVR. 
Chest radiography was performed after 2 h and on the next morn-
ing to exclude pneumothorax and to examine the occurrence of 
target lobe atelectasis. Patients were informed about the possibil-
ity of a late pneumothorax after discharge.
 Follow-Up 
 Efficacy follow-ups were performed at 30 days and at 90 days 
after BLVR. Pulmonary function tests, 6-minute walk test, and 
chest radiography were repeated at each follow-up. A CT scan was 
occasionally performed at follow-up.
 For safety analysis, all complications were recorded during the 
whole course of patient follow-up. Target lobe atelectasis was as-
sessed by X-ray and classified as “full atelectasis” when it could be 
observed on X-ray, as “sign of atelectasis” when a rise of the dia-
phragm or an ipsilateral mediastinal shift was present, and as “no 
atelectasis” when none of the above signs were present. Two radi-
ologists interpreted each chest radiograph together.
 Statistical Analysis 
 The Student  t test for paired samples was used to examine mean 
differences in changes from baseline to follow-up values. Inten-
tion-to-treat analyses were performed on all end points. An in-
crease of >10% in FEV 1  [8] and of >26 m in the 6-minute walk test 
 [9] as well as a reduction of  ≥ 430 mL in residual volume  [10] were 
considered requirements for a minimal clinically important differ-
ence. A  p value of <0.05 was considered statistically significant.
 Results 
 Baseline Characteristics and Procedural Results 
 Twenty consecutive patients referred to our bronchos-
copy unit between January 2013 and August 2015 with 
very severe emphysema and treated with Zephyr © valves 
for BLVR fulfilled the inclusion criteria and were included 
in our analysis. Baseline data are presented in detail in 
 Table 1 . Three out of 20 patients (15%) had homozygote 
α1-antitrypsin deficiency. At baseline, 18/20 patients 
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(90%) needed supplemental oxygen and 2/20 patients 
(10%) required noninvasive ventilation. Coronary heart 
disease, osteoporosis, and arterial hypertension were pres-
ent in 7, 6, and 2 subjects, respectively. Mild pulmonary 
hypertension, assessed by echocardiography, was present 
in 12 out of 20 patients (60%) with a systolic pulmonary 
artery pressure ranging from 26 to 39 mm Hg. The sys-
tolic pulmonary artery pressure of the remaining 8 pa-
tients was  ≤ 25 mm Hg. Two patients were listed for lung 
transplantation. Ten patients (50%) presented with very 
heterogeneously distributed emphysema according to 
HRCT and perfusion scan read by experienced physicians 
and discussed during the multidisciplinary conference. 
Chartis measurement was performed in all patients. In 3 
patients, a low-flow pattern was revealed, and collateral 
ventilation could be excluded in the rest of the patients.
 The treated lobes can be seen in  Table 2 . Complete lo-
bar occlusion was achieved using 1–8 valves (median 3) 
per patient.
 Safety 
 All patients were followed for at least 90 days for ad-
verse events. Complications recorded are listed in  Ta-
ble 3 . Four patients (20%) developed a pneumothorax, all 
of which occurred within 24 h after BLVR, 1 with tension 
pneumothorax and rapid deterioration. A chest tube was 
immediately placed to prevent respiratory failure. In 2 pa-
tients, chest tube placement and suction alone success-
fully treated the air leaks. In the other 2 patients, valve 
removal and thoracoscopy were needed to treat persistent 
air leaks. One patient requested and underwent valve re-
moval after 3 months due to lack of respiratory improve-
ment. These 3 patients were included in the efficacy anal-
ysis and in the safety analysis. A mild COPD exacerbation 
and pneumonia in a nontreated lobe occurred in 2 pa-
tients. In 1 patient, a loss of atelectasis was resolved fol-
lowing an bronchoscopic review and a position change 
for 1 of the valves. Data for the 3-month follow-up were 
taken after this revision date. Respiratory failure requir-
ing mechanical ventilation was not observed in any pa-
tient. No patient died within the mean observation time 
of 21 ± 8 months (range 9–33).
 Outcome Measurements 
 Radiography 
 Thirty days after valve implantation, evidence of suc-
cessful lung volume reduction was observed on chest radi-
ography after BLVR in 13 cases (65%). In 7 of these patients 
(35%), chest radiography revealed a complete atelectasis of 
the treated lobe, while in the other 6 patients, signs of atel-
ectasis were detected by an upward rise of the hemidia-
phragm and an ipsilateral mediastinal shift ( Table 2 ). Lung 
volume reduction that had been achieved after 1 month 
persisted at the 3-month follow-up in all patients.
 Lung Function and Exercise Tolerance 
 The pulmonary function test results and the 6-minute 
walk test results at baseline and at 30 and 90 days after 
 Table 1.  Baseline characteristics of low-FEV1 patients who under-
went bronchoscopic lung volume reduction with valves
Patients, n 20
Gender, male/female 11/9
Age, years 59.3 ± 5.9
Homozygote α1-antitrypsin deficiency 3/20 (15)
Very heterogeneous emphysema 10/20 (50)
BMI 22.0 ± 3.6
FEV1, L 0.52 ± 0.12
FEV1 % 17.8 ± 1.9
RV, L 7.5 ± 1.6
RV % 315 ± 70
IVC, L 1.75 ± 0.58
IVC % 49.2 ± 12.3
DLCO % 21.5 ± 8.8
6-MWD, m 283 ± 66
Oxygen supplementation 18/20 (90)
Noninvasive ventilation 2/20 (10)
Mild pulmonary hypertension 12/20 (60)
 Values are means ± standard deviations or numbers with per-
centages in parentheses. BMI, body mass index; FEV1, forced ex-
piratory volume in 1 s; RV, residual volume; IVC, inspiratory vital 
capacity; DLCO, diffusing capacity of the lung for carbon monox-
ide; 6-MWD, 6-minute walking distance.
 Table 2.  Target lobe and atelectasis assessment 30 days after BLVR
Patients Full TL 
atelectasis
Signs of TL 
atelectasis
No signs of 
atelectasis
RUL 5 1 1 3
RML 1 0 1 0
RLL 3 0 1 2
LUL 6 3 2 1
LLL 5 3 1 1
Total 20 7 6 7
 Values are numbers. BLVR, bronchoscopic lung volume reduc-
tion; TL, target lobe; RUL, right upper lobe; RML, right middle 
lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower 
lobe.
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BLVR are shown in  Table 4 . FEV 1 and residual volume 
improved significantly 30 days after BLVR and were 
maintained afterwards at 90 days. At 30 days 10/17 pa-
tients (59%) and at 90 days 8/17 patients (47%) reached 
the criteria for a minimal clinically important difference 
in FEV 1 (i.e., >10%). And at 30 days 10/17 patients (59%) 
and at 90 days 10/17 patients (59%) reached the criteria 
for a minimal clinically important difference in residual 
volume (–430 mL).
 The 6-minute walking distance increased at 1 month 
and at 3 months. Six out of 17 patients (35%) and 9/17 
patients (53%) improved meaningfully (>26 m) after 30 
and 90 days, respectively.
 Impact of Atelectasis on Functional Outcome 
 Table 5 shows the impact of atelectasis on clinical out-
come. At 90 days, 10/17 patients (58%) displayed a full 
atelectasis or signs of atelectasis on chest X-ray. These 
patients showed a larger increase in FEV 1 than those 
without atelectasis (0.2 ± 0.2 vs. 0 ± 0.1 L,  p < 0.01), while 
the 6-minute walk test did not reach a statistically signif-
icant difference between these 2 groups (52.5 ± 98.9 vs. 
16.7 ± 58.5 m,  p = 0.41).
 Table 3.  Complications observed within 30 days after BLVR
Events n Treatments
Intraoperative/perioperative 
pneumothorax
4 VATS (2), drainage (2)
Late pneumothorax 0 –
Pneumonia 3 antibiotics
Exacerbations 2 antibiotics
Respiratory insufficiency 0 –
Loss of atelectasis 1 valve removal + valve 
reimplantation
Respiratory insufficiency 0 –
Death 0 –
Removal of valves (patient’s 
request) 
1 listed for LuTx
 BLVR, bronchoscopic lung volume reduction; VATS, video-
assisted thoracoscopic surgery; LuTx, lung transplantation.
 Table 4.  Outcome (intention-to-treat-analysis): changes in lung function and exercise capacity 30 and 90 days after bronchoscopic lung 
volume reduction with valves
After 30 days  After 90 days
range mean ± SD p value ra nge mean ± SD p value 
Δ FEV1, L –0.10 to +0.30 +0.12 ± 0.13 <0.01 –0.08 to +0.55 +0.10 ± 0.16 <0.05
Δ FEV1 % from baseline –16.4 to +75 +25.2 ± 29.6 –11.7 to +110 +22.8 ± 32.9
Δ RV, L –4.1 to +1.1 –1.1 ± 1.3 <0.01 –4.2 to +1.6 –1.14 ± 1.79 <0.05
Δ RV % from baseline –52.6 to +16.9 –13.4 ± 19.3 –43.4 to +18.1 –12.5 ± 23.3
Δ IVC, L –0.79 to +0.92 +0.25 ± 0.47 n.s. –0.59 to +1.84 +0.29 ± 0.64 n.s.
Δ IVC % from baseline –38.6 to +53.9 +17.1 ± 26.6 –25.3 to +143.8 +22.3 ± 42.5
Δ 6-MWD, m –130 to +130 +10 ± 68 n.s. –80 to +205 +33.0 ± 76.3 n.s.
Δ 6-MWD % from baseline –61.9 to +60 +4.1 ± 33.2 –21.1 to +102.5 +18 ± 34.6
 p values in italics are statistically significant. FEV1, forced expiratory volume in 1 s; RV, residual volume; IVC, inspiratory vital ca-
pacity; 6-MWD, 6-minute walking distance; n.s., not significant.
 Table 5.  Comparison of changes in lung function and exercise ca-
pacity 90 days after BLVR with valves between the atelectasis and 
the nonatelectasis group
Atelectasis or 
sign of atelectasis
No sign of 
atelectasis
p value
Patients, n 10 7
Δ FEV1, L  + 0.2 ± 0.2  – 0.0 ± 0.1 <0.01
Δ RV, L –1.49 ± 1.45 –0.63 ± 0.89 0.18
Δ 6-MWD, m +52.5 ± 98.8 +16.7 ± 58.5 0.41
 BLVR, bronchoscopic lung volume reduction; FEV1, forced ex-
piratory volume in 1 s; RV, residual volume; 6-MWD, 6-minute 
walking distance.
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 Discussion 
 In the present study, we analyzed the safety and out-
comes of BLVR with endobronchial valves in patients 
with FEV 1  ≤ 20% predicted. Patients’ FEV 1 and the 6-min-
ute walking distance after 30 and 90 days improved. The 
rate of complications was not higher than that reported 
for emphysema patients with better lung function, i.e., 
FEV 1 >20%, and treated with BLVR  [3] .
 Patients with very severe COPD suffer from agonizing 
dyspnea and diminished quality of life  [11] . As inhaler 
medications have been tested almost entirely on moder-
ately affected COPD patients, evidence regarding their ef-
ficacy in the group of patients with FEV 1  ≤ 20% predicted 
is scarce. Patients with COPD GOLD stage IV are under-
represented or excluded in the vast majority of clinical 
COPD studies. Although lung transplantation might be 
an option for younger patients, the rate of lung deteriora-
tion for emphysema is slower than for other disorders, 
such as cystic fibrosis and idiopathic pulmonary fibrosis. 
Therefore, with the new allocation scoring systems, em-
physema patients rarely gain priority on lung transplant 
waiting lists  [12] . For this group of patients, a nontrans-
plant therapy that improves exercise capacity and quality 
of life is urgently needed.
 In the NETT trial, the mortality of patients submitted 
to surgical lung volume reduction was significantly high-
er for patients with FEV 1  ≤ 20% predicted  [1] than for 
those with higher FEV 1 . This is the reason why patients 
with very low predicted FEV 1 % were excluded from early 
trials of BLVR  [13] . Although a lower threshold of FEV 1 
15% predicted was chosen in the VENT trial, the mean 
predicted FEV 1 of the patients in the study was 30%, in-
dicating that the majority, if not all of the study patients, 
had a predicted FEV 1 above the threshold of 20%. In sub-
sequent controlled trials, only few low-FEV 1 predicted 
patients (3 in BeLieVeR-HIFi and 5 in STELVIO [pers. 
commun.]) were included  [3, 14] .
 Hyperinflation is related to a reduced exercise capac-
ity leading to limited daily activities of the affected pa-
tients, a meaningful factor for a decreased quality of life 
 [15–17] . Patients with severe hyperinflation are appropri-
ate candidates for BLVR  [4, 14] . It is known that with in-
creasing severity of the disease and worsening airflow, 
there is also an increase in hyperinflation  [15, 18] . It can 
be expected that patients with very severe COPD, as indi-
cated by limited airflow, are patients who will benefit 
from BLVR therapy. Therefore, the procedure should be 
offered as an option to this patient population.
 Taking into account the decreased lung function and 
the high levels of comorbidity, safety issues are of para-
mount importance when treating low-FEV 1 patients. Im-
proved patient selection is the reason for an increasing 
post-BLVR pneumothorax rate, up to 23% in recent years 
 [19] . The pneumothorax rate after BLVR found in our 
study (i.e., 20%) is comparable to the rate described in the 
literature  [20] . Developing a pneumothorax after BLVR 
is considered as a predictor of clinical success in the long 
term. A mean target lobe volume reduction of 65% was 
observed to lead to improvements in terms of lung func-
tion and quality of life in the patients studied by Gompel-
mann et al.  [20] . However, patients are at risk for peripro-
cedural pneumothorax, sometimes tension pneumotho-
rax, leading to a highly acute emergency situation, 
particularly in the first 72 h after BLVR  [20] . When this 
occurs, immediate placement of a chest tube is necessary 
to prevent respiratory failure. In our institution, patients 
are supervised for 24 h in the ICU and are not discharged 
before the fourth day after BLVR. In 4 patients of the pres-
ent cohort, chest tube placement could be performed im-
mediately because of the close 24-h supervision in the 
ICU. We, therefore, believe that close supervision, prefer-
ably in the ICU for at least 24 h after the bronchoscopic 
procedure, provides optimal patient care and improve-
ment in outcome.
 Ventilatory insufficiency is frequently present in low-
FEV 1 patients  [21] . COPD exacerbation is a known com-
plication after BLVR that might lead to an increased re-
spiratory effort. It is, therefore, important to emphasize 
that for all patients with ventilatory insufficiency, non-
invasive ventilation has to be implemented before
valve placement. However, positive-pressure ventilation 
should be withdrawn immediately after BLVR to prevent 
tension pneumothorax.
 The low-FEV 1 patients treated with BLVR in this study 
showed improvements in lung function tests and exercise 
capacity comparable to patients with better pre-BLVR 
lung function  [3, 4] . Therefore, the clinical improvements 
derived from BLVR with valves seem to be independent 
of pretreatment FEV 1 level. Consequently, BLVR with 
endobronchial valves may also be considered in this se-
verely impaired group of patients when collateral ventila-
tion of the target lobe is excluded. When radiologically 
confirmed lung volume reduction was achieved, patients 
enjoyed a substantial physiological benefit.
 The limitations of this study are the retrospective na-
ture of the analysis, a lack of quality of life data before and 
after treatment, and also the missing volumetric HRCT 
scan software, as emphysema quantification might im-
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prove target lobe selection. Because this study cohort is 
relatively small, further prospective studies including 
quality of life data and software-based emphysema quan-
tification to confirm efficacy of BLVR in low-FEV 1 pa-
tients are needed.
 Conclusion 
 The results of this study show for the first time that, in 
the hands of an experienced team, BLVR with valve place-
ment is feasible even in emphysema patients with low 
FEV 1 of  ≤ 20% predicted. This can be achieved without an 
increase in complication rates when patients are selected 
by an experienced multidisciplinary team and intensively 
monitored after the procedure.
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